Targeted Treatments in Cancer 2.0
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".
Deadline for manuscript submissions: 30 September 2024 | Viewed by 1463
Special Issue Editor
Interests: biochemistry; radiobiology; pharmacology; molecular science; radiochemistry
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This Special Issue is a continuation of our previous Special Issue, entitled "Targeted Treatments in Cancer".
In recent years, the survival rate of cancer patients has increased, due to the development of various treatments. However, some cancers, such as pancreatic cancer, are extremely resistant to treatment. One approach uses antibodies or chemicals conjugated to radionuclides, which provide specific radiotherapy. Several cancer-specific molecular targets (such as LAT1, highly expressed in tumor tissues) have been selected, and antibodies (i.e., 90Y-CD20 and 111In-CD20 antibodies, Zevalin®) have also been selected. Nuclear medicine treatment is less invasive than surgery, and is suitable for difficult-to-treat cancer cases. In particular, targeted α therapy (TAT) involves the selective delivery of α-emitters to tumors, using high linear energy transfer (LET) α-particles, while minimizing the damage caused to surrounding tissues. Radium-223 (223Ra) dichloride has been employed as a treatment for bone metastasis (i.e., Xofigo®), as well as for pain management. Radiopharmaceuticals constitute a practical and effective treatment, albeit with their restrictions. Actinium-225 (225At) and astatine-211 (211At) are promising radionuclides for TAT.We focus on researching the usefulness of nuclear medicine treatments, and we aim to drive the development of novel therapeutic agents. Since molecular biology and basic scientific studies are indispensable for the development of technology in nuclear medicine, we will prioritize basic research over clinical trials/data.
Prof. Dr. Kazuko Kaneda-Nakashima
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- TAT (targeting alpha therapy)
- nuclear medicine
- cancer treatment
- imaging
- radioisotope (RI)
- surface marker
- TRT (targeted radioisotope therapy)
